JG
KALV

Jefferies Group’s KalVista Pharmaceuticals KALV Stock Holding History

Jefferies Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$196K Buy
+13,500
New +$189K ﹤0.01% 1370
2019
Q4 		– Sell
-11,250
Closed -$131K – 2758
2019
Q3 		$131K Buy
+11,250
New +$182K ﹤0.01% 2459

Other funds holding KALV

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jefferies Group's KALV Position: Q3 2022 in Review

Jefferies Group opened a new position in KalVista Pharmaceuticals (KALV) in Q3 2022: 13,500 shares worth $196K. The stake represents ﹤0.01% of the portfolio and ranks #1370 among its holdings. This is a return to the name: Jefferies Group previously reported a position in KALV as recently as Q3 2019.

Jefferies Group first reported a position in KALV in Q3 2019 and has held it in 2 quarters since. 94 funds tracked by Wall St. Rank hold KALV as of Q3 2022.

  • Jefferies Group held 13,500 shares of KalVista Pharmaceuticals worth $196K as of Q3 2022.
  • KalVista Pharmaceuticals was a new Jefferies Group position in Q3 2022.
  • KalVista Pharmaceuticals made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1370 holding.
  • Jefferies Group first reported a position in KalVista Pharmaceuticals in Q3 2019 and has held it in 2 quarters since.
  • 94 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.